AI and Ozempic: The two great disruptive tech...

On today’s episode, host Josh Christensen is joined by ‘Fast Company’ associate editor David Salazar to help break down the latest news in the world of business and innovation, including the fallout from DeepSeek’s LLM launch, the backtracked federal funding freeze, and the risin ...  Show more

Police departments across the country are embracing AI-enhanced surveillance technology in the name of stopping crime. One prominent security firm called Flock Safety is leading the effort and profiting off our fears. Fast Company Senior Writer Ainsley Harris joined Yaz and Josh ...  Show more

You may have heard about Ozempic, Wegovy and Mounjaro. It’s tough to miss the online chatter, the ads on TV and all the news coverage. They are part of a class of drugs originally designed to treat diabetes, and all three have been shown to help people lose significant amounts of ...  Show more

From Elon Musk to several Hollywood celebrities, the weight loss wonder drug, semaglutide, is taking the world by storm. What was an unintended consequence of a diabetes control med, the emergence of significant weight loss has raised the expectation of the wonder drug becomin ...

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more

Bloomberg News Health Reporter Madison Muller discusses how the drug Ozempic could cut demand for big-money drugs targeting a wide range of maladies, even Alzheimer’s. Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.See omnystudio.com/listener for privacy information ...  Show more